Physician profile
Mary E Conley
NPI 1922166909
$858.34
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $846 · 2022: $11.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $205.84 | 2021 | |
| Astellas Pharma US INC | $99.05 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.41 | 2021 | |
| Novo Nordisk INC | $79.35 | 2021 | |
| Amarin Pharma, INC. | $70.62 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $55.34 | 2021 | |
| Lilly USA, LLC | $51.51 | 2021 | |
| Glaxosmithkline, LLC. | $41.94 | 2021 | |
| Pfizer INC. | $38.83 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $38.00 | 2021 | |
| Esperion Therapeutics, INC. | $24.18 | 2021 | |
| Janssen Pharmaceuticals, INC | $23.63 | 2021 | |
| Merck Sharp & Dohme LLC | $17.60 | 2021 | |
| Virtus Pharmaceuticals LLC | $17.04 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Conley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.